Prevention and management of adverse events related to regorafenib

Lipid Management Strategies for the Prevention of Adverse Cardiovascular Events

Accessible online at: www.karger.com/hed As the leading cause of death and a tremendous source of morbidity worldwide [1], atherosclerotic coronary artery disease (CAD) and its treatment and prevention represent one of the greatest challenges facing health care. Aggressive efforts at educating the public about CAD and identifying high-risk individuals as part of primary prevention of CAD are ne...

Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management

Immunotherapy is one of the most recent systemic treatments to emerge for use in oncology, and is based on the blocking of inhibitory immune checkpoints to potentiate the immune response to cancer. The anti-cytotoxic T lymphocyte-associated antigen-4 antibody ipilimumab and anti-programmed cell death protein 1 antibodies, including nivolumab and pembrolizumab, are currently available and widely...

Pharmacogenetics to predict drug-related adverse events.

Identification of reliable markers to predict drug-related adverse events (DRAEs) is an important goal of the pharmaceutical industry and others within the healthcare community. We have used genetic polymorphisms, including the most frequent source of variation (single nucleotide polymorphisms, SNPs) in the human genome, in pharmacogenetic approaches designed to predict DRAEs. Three studies exe...

Combined Leucopenia and Thrombocytopenia Are Possibly Adverse Events of Lamotrigine

Normal 0 false false false MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0c...

HIV-related TB and adverse drug events.